全文获取类型
收费全文 | 5194篇 |
免费 | 261篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 82篇 |
妇产科学 | 63篇 |
基础医学 | 649篇 |
口腔科学 | 80篇 |
临床医学 | 303篇 |
内科学 | 1508篇 |
皮肤病学 | 43篇 |
神经病学 | 429篇 |
特种医学 | 194篇 |
外科学 | 938篇 |
综合类 | 37篇 |
预防医学 | 147篇 |
眼科学 | 138篇 |
药学 | 335篇 |
中国医学 | 9篇 |
肿瘤学 | 493篇 |
出版年
2023年 | 24篇 |
2022年 | 44篇 |
2021年 | 88篇 |
2020年 | 41篇 |
2019年 | 63篇 |
2018年 | 85篇 |
2017年 | 74篇 |
2016年 | 73篇 |
2015年 | 88篇 |
2014年 | 121篇 |
2013年 | 150篇 |
2012年 | 276篇 |
2011年 | 299篇 |
2010年 | 168篇 |
2009年 | 166篇 |
2008年 | 265篇 |
2007年 | 305篇 |
2006年 | 288篇 |
2005年 | 314篇 |
2004年 | 307篇 |
2003年 | 281篇 |
2002年 | 289篇 |
2001年 | 147篇 |
2000年 | 138篇 |
1999年 | 143篇 |
1998年 | 73篇 |
1997年 | 48篇 |
1996年 | 48篇 |
1995年 | 45篇 |
1994年 | 49篇 |
1993年 | 41篇 |
1992年 | 101篇 |
1991年 | 73篇 |
1990年 | 75篇 |
1989年 | 93篇 |
1988年 | 83篇 |
1987年 | 65篇 |
1986年 | 51篇 |
1985年 | 56篇 |
1984年 | 41篇 |
1983年 | 42篇 |
1982年 | 21篇 |
1981年 | 17篇 |
1980年 | 23篇 |
1979年 | 24篇 |
1977年 | 19篇 |
1976年 | 16篇 |
1973年 | 17篇 |
1969年 | 18篇 |
1966年 | 15篇 |
排序方式: 共有5492条查询结果,搜索用时 24 毫秒
61.
Akihiro Konno Miho Kudo Tsuyoshi Ichihara Masahiko Yamagami Seiki Horita Kazunori Ohama Kazuhisa Taketa Shoichi Koizumi 《Pediatrics international》1998,40(5):466-469
Abstract Background: Yolk sac tumors (YST) exhibit several different histological subtypes and the mechanisms of cellular differentiation and prognosis of each subtype remain unknown.
Results: We report two infants with sacrococcygeal YST; one represented a typical histological subtype and the other showed a hepatoid subtype with uniform histology. The isoform of alpha-fetoprotein (AFP) in the patient with the hepatoid pattern was examined by lectin-affinity Immunoelectrophoresis and represented as a YST. but not hepatocellular, subtype. The patient with typical YST responded well to VAB-6 combination chemotherapy. However, this regimen was only partially effective to the patient with the pure hepatoid histological subtype, and an etoposide with ifosfamide and cisplatin (VIP) regimen as a salvage chemotherapy combined with complete tumor resection was useful to achieve complete remission (CR). Both of the patients have been in CR for more than four years. 相似文献
Results: We report two infants with sacrococcygeal YST; one represented a typical histological subtype and the other showed a hepatoid subtype with uniform histology. The isoform of alpha-fetoprotein (AFP) in the patient with the hepatoid pattern was examined by lectin-affinity Immunoelectrophoresis and represented as a YST. but not hepatocellular, subtype. The patient with typical YST responded well to VAB-6 combination chemotherapy. However, this regimen was only partially effective to the patient with the pure hepatoid histological subtype, and an etoposide with ifosfamide and cisplatin (VIP) regimen as a salvage chemotherapy combined with complete tumor resection was useful to achieve complete remission (CR). Both of the patients have been in CR for more than four years. 相似文献
62.
Shoichi Ebisuno Takeshi Inagaki 《International journal of clinical oncology / Japan Society of Clinical Oncology》1998,3(4):253-256
Urinary bladder cancers occurring after prolonged cyclophosphamide therapy are being increasingly reported. Cyclophosphamide-induced
cancer in the upper urinary tract is not, however, generally recognized. We report a case of asynchronous development of transitional
cell carcinoma in the bladder and renal pelvis, after prolonged cyclophosphamide therapy for non-Hodgkin's lymphoma. To date,
at least 8 cyclophosphamide-related cancers have been reported in the upper tract. These cases are reviewed briefly. 相似文献
63.
64.
N Kikuchi M Kanai N Kita Y Mitsuhashi I Konishi 《International journal of gynaecology and obstetrics》2006,94(1):62-66
Buerger's disease is an inflammatory occlusive vascular disorder involving small- and medium-sized arteries in the distal extremities and is usually complicated with thrombophlebitis. Since Buerger's disease develops most frequently in men who smoke, pregnancy complicated with this disease is extremely rare. Only three pregnancies have been reported previously. All cases indicate that Buerger's disease worsens during pregnancy. However, anti-coagulant therapy appeared to be effective in this case. Accordingly, careful observation is mandatory in pregnancies complicated with Buerger's disease. 相似文献
65.
Tetsuya Mitsudomi Takayuki Kosaka Hideki Endoh Yoshitsugu Horio Toyoaki Hida Shoichi Mori Shunzo Hatooka Masayuki Shinoda Takashi Takahashi Yasushi Yatabe 《Journal of clinical oncology》2005,23(11):2513-2520
PURPOSE: To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection. PATIENTS AND METHODS: We sequenced exons 18-21 of the EGFR gene using total RNA extracted from 59 patients with lung cancer who were treated with gefitinib for recurrent lung cancer. Gefitinib effectiveness was evaluated by both imaging studies and change in serum carcinoembryonic antigen (CEA) levels. RESULTS: EGFR mutations were found in 33 patients (56%). Of these mutations, 17 were deletions around codons 746-750 and 15 were point mutations (12 at codon 858, three at other codons), and one was an insertion. EGFR mutations were significantly more prevalent in females, adenocarcinoma, and never-smokers. Gefitinib treatment resulted in tumor shrinkage and/or CEA decrease to less than half of the baseline level in 26 patients, tumor growth and/or CEA elevation in 24 patients, and gefitinib effect was not assessable in nine patients. Female, never-smoking patients with adenocarcinoma tended to respond better to gefitinib treatment. Gefitinib was effective in 24 of 29 patients with EGFR mutations, compared with two of 21 patients without mutations (P < .0001). Of note, del746-750 might be superior to L858R mutations for prediction of gefitinib response. Patients with EGFR mutations survived for a longer period than those without the mutations after initiation of gefitinib treatment (P = .0053). CONCLUSION: EGFR mutations were a good predictor of clinical benefit of gefitinib in this setting. 相似文献
66.
67.
Yumie Takeshita Yuki Kita Takeo Tanaka Hisanori Goto Yujiro Nakano Chisato Teramura Yasufumi Enyama Toshinari Takamura the Establishment of Rationale for Antiaging Diabetic Medicine Study Group 《Journal of diabetes investigation.》2022,13(6):965
Aims/IntroductionGlucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study. To examine this hypothesis clinically, we compared the glucose‐lowering effects of GLP‐1 receptor agonist liraglutide with and without prior glycemic control.Materials and MethodsIn an open‐label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once‐daily insulin therapy, degludec (Insulin–GLP‐1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GLP‐1 RA, liraglutide (GLP‐1 RA first group, 0.9 mg), for 24 weeks. The primary efficacy end‐points consisted of changes in the levels of fasting plasma glucose and glycated hemoglobin (HbA1c).ResultsThe median fasting plasma glucose and HbA1c before the study were 210.0 mg/dL and 9.8%, respectively. The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin–GLP‐1 RA relay group (P < 0.001) and GLP‐1 RA first group (P < 0.001) by week 24, although no intergroup differences were observed. The reduction of HbA1c in the Insulin–GLP‐1 RA relay group tended to be larger than that in the GLP‐1 RA first group in the lowest CPR (C‐peptide immunoreactivity) quartile (P = 0.072). The adverse events consisted of gastrointestinal problems, followed by hypoglycemia.ConclusionsThe GLP‐1 receptor agonist is overall effective without prior glycemic control with insulin in participants with poorly controlled type 2 diabetes. However, in participants with insulinopenic type 2 diabetes, prior glycemic control with insulin might overcome glucose toxicity‐induced GLP‐1 resistance. 相似文献
68.
69.
Nozomi Kita Yuta Shibamoto Shinya Takemoto Yoshihiko Manabe Takeshi Yanagi Chikao Sugie Natsuo Tomita Hiromitsu Iwata Taro Murai Shingo Hashimoto Satoshi Ishikura 《Journal of radiation research》2022,63(4):666
The outcomes of three methods of intensity-modulated radiation therapy (IMRT) for localized prostate cancer were evaluated. Between 2010 and 2018, 308 D’Amico intermediate- or high-risk patients were treated with 2.2 Gy daily fractions to a total dose of 74.8 Gy in combination with hormonal therapy. Overall, 165 patients were treated with 5-field IMRT using a sliding window technique, 66 were then treated with helical tomotherapy and 77 were treated with volumetric modulated arc therapy (VMAT). The median age of patients was 71 years. The median follow-up period was 75 months. Five-year overall survival (OS) and biochemical or clinical failure-free survival (FFS) rates were 95.5 and 91.6% in the 5-field IMRT group, 95.1 and 90.3% in the tomotherapy group and 93.0 and 88.6% in the VMAT group, respectively, with no significant differences among the three groups. The 5-year cumulative incidence of late grade ≥2 genitourinary and gastrointestinal toxicities were 7.3 and 6.2%, respectively, for all patients. Late grade ≥2 gastrointestinal toxicities were less frequent in patients undergoing VMAT (0%) than in patients undergoing 5-field IMRT (7.3%) and those undergoing tomotherapy (11%) (P = 0.025), and this finding appeared to be correlated with the better rectal DVH parameters in patients undergoing VMAT. Other toxicities did not differ significantly among the three groups, although bladder dose-volume parameters were slightly worse in the tomotherapy group than in the other groups. Despite differences in the IMRT delivery methods, X-ray energies and daily registration methods, all modalities may be used as IMRT for localized prostate cancer. 相似文献
70.
Hirotomo Dochi Satoru Kondo Takayuki Murata Masaki Fukuyo Asuka Nanbo Kousho Wakae WenPing Jiang Toshihide HamabeHoriike Mariko Tanaka Takumi Nishiuchi Harue Mizokami Makiko MoriyamaKita Eiji Kobayashi Nobuyuki Hirai Takeshi Komori Takayoshi Ueno Yosuke Nakanishi Miyako Hatano Kazuhira Endo Hisashi Sugimoto Naohiro Wakisaka ShinHun Juang Masamichi Muramatsu Atsushi Kaneda Tomokazu Yoshizaki 《Cancer science》2022,113(8):2862